Dirlei Nico

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Ciências da Saúde

Unidade:

Instituto de Microbiologia

Departamento:

Departamento de Microbiologia Geral/IM

ORCID:

não disponível no Lattes


Formação:

  • Universidade Federal do Rio de Janeiro

    | Pós-Doutorado | 2015 - Agora

  • Universidade Federal do Rio de Janeiro

    | Pós-Doutorado | 2010 - 2015

  • Universidade Federal do Rio de Janeiro

    Ciências (Microbiologia) | Doutorado | 2006 - 2010

  • Universidade Federal do Rio de Janeiro

    Ciências (Microbiologia) | Mestrado | 2005 - 2006

  • Universidade Federal do Rio de Janeiro

    Microbiologia | Aperfeiçoamento | 2004 - 2005

  • UNIVERSIDADE DE VASSOURAS

    Farmácia e Bioquímica | Graduação | 2000 - 2004
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:

(69.44% artigos com DOI)

Titulo DOI Ano
In vitro and in vivo effects of digoxin derivatives on promastigotes and amastigotes of Leishmania infantum 10.1080/16583655.2023.2289240 2024
Drugs and nanoformulations for the management of infection: a patent and literature review (2015-2022) 10.1080/13543776.2023.2201431 2023
Anti-Leishmania amazonensis Activity, Cytotoxic Features, and Chemical Profile of Allium sativum (Garlic) Essential Oil 10.3390/tropicalmed8070375 2023
Cellular-Host Interaction of SARS-CoV-2 Gamma Variant 2023
Necrotizing Myopathy in SARS-CoV-2 Infection 2022
Humoral response in Leishmaniasis 10.3389/fcimb.2022.1063291 2022
Antileishmanial screening, cytotoxicity, and chemical composition of essential oils: a special focus on Piper callosum essential oil 10.1002/cbdv.202200689 2022
Inactivation of avian influenza viruses by hydrostatic pressure as a potential vaccine development approach 10.1099/acmi.0.000220 2021
The Delay in the Licensing of Protozoal Vaccines: A Comparative History 10.3389/fimmu.2020.00204 2020
Coronavírus: histórico e potenciais vacinas 2020
The F1F3 Recombinant Chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and Its Epitopes Induce Cross-Protection Against Leishmania (V.) braziliensis Infection in Mice 10.3389/fimmu.2019.00724 2019
Prevalence of IgG Autoantibodies against GD3 Ganglioside in Acute Zika Virus Infection 10.3389/fmed.2018.00025 2018
NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis 2018
A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection 2017
Dependency of B-1 Cells in the Maintenance of Splenic Interleukin-10 Producing Cells and Impairment of Macrophage Resistance in Visceral Leishmaniasis 10.3389/fmicb.2017.00978 2017
F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis 10.3389/fimmu.2017.00750 2017
Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis 10.3389/fimmu.2017.00227 2017
Expression of leukosialin (CD43) defines a major intrahepatic T cell subset associated with protective responses in visceral leishmaniasis 10.1186/s13071-015-0721-9 2015
Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro 2015
Intranasal immunization with pressure inactivated avian influenza elicits cellular and humoral responses in mice 2015
Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis 10.1371/journal.pntd.0004297 2015
Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains 10.3389/fimmu.2014.00189 2014
Vaccination with Nucleoside hydrolase (NH36) of L.(L.) donovani or its C-terminal portion (F3) in formulation with saponin prevents the increase of the proportions of spleen dendritic cells in murine experimental visceral leishmaniasis 2014
Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection 10.3389/fimmu.2014.00273 2014
Full Inactivation of Human Influenza Virus by High Hydrostatic Pressure Preserves Virus Structure and Membrane Fusion While Conferring Protection to Mice against Infection 10.1371/journal.pone.0080785 2013
The Leishmune's Nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis 2012
The adjuvanticity of Chiococca alba saponins increases with the length and hydrophilicity of their sugar chains 2012
Mice vaccination with high hydrostatic pressure-inactivated H3N8 virus protects against experimental avian Flu 2012
Kinetics and docking studies of two potential new inhibitors of the nucleoside hydrolase from Leishmania donovani 10.1016/j.ejmech.2012.07.052 2012
Resistance to visceral leishmaniasis is severely compromised in mice deficient of Bradykinin B2-Receptors 10.1186/1756-3305-5-261 2012
Adaptive Immunity against Leishmania Nucleoside Hydrolase Maps its C-terminal Domain as the Target of the CD4+ T Cell Driven Protective Response 10.1371/journal.pntd.0000866 2010
Cloning of the Nucleoside hydrolase of Leishmania donovani aiming at the development of a synthetic vaccine against visceral leishmaniasis 10.1016/j.provac.2009.07.021 2009
FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine 10.1586/14760584.7.6.833 2008
The FML vaccine (Leishmune (R)) against canine visceral leishmaniasis: a transmission blocking vaccine 10.1016/j.vaccine.2005.11.061 2006
Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis 10.1016/j.vaccine.2006.02.034 2006
Assessment of the monoterpene, glycidic and triterpene-moieties contributions to the adjuvant function of the CP05-saponin of Calliandra pulcherrima Benth during vaccination against experimental visceral leishmaniasis 10.1016/j.vaccine.2006.08.035 2006
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
11ª Semana de Integração Acadêmica da UFRJ 2022
Associação da produção das citocinas TNF-alfa e IL-10, com o processo de cicatrização de incisões operatórias na parede abdominal em ratos Wistar (Rattus norvegicus). 2018
Identification of conserved linear epitope as target of protective antibodies in visceral leishmaniasis 2018
Challenges and solutions to tailor an anti-leishmania vaccine to the needs of specific regions: a nanomedical approach 2017
Immunotherapy against visceral leishmaniasis caused by L. (L.) chagasi with the recombinant chimera containing the N- and C- domains of Leishmania (L.) donovani nucleoside hidrolase 2016
F2 DOMAIN OF LEISHMANIA NUCLEOSIDE HYDROLASE INDUCES RESISTENCE-ASSOCIATED T-CELL RESPONSES IN HUMAN VISCERAL LEISHMANIASIS 2016
IMMUNOTHERAPY AGAINST VISCERAL LEISHMANIASIS CAUSED BY L.(L) CHAGASI WITH THE RECOMBINANT CHIMERA CONTAINING THE N- AND C- DOMAINS OF LEISHMANIA (L.) DONOVANI NUCLEOSIDE HYDROLASE 2016
The F1 domain is the antibody target of L. (L.) donovani Nucleoside hydrolase NH36 in subclinical DTH+ and cured human patients of visceral leishmaniasis from Aracaju (SE). 2014
Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+ epitopes of Leishmania donovani nucleoside hydrolase terminal domains. 2014
. Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection 2014
. Multifuncional TH1 cell response against nucleoside hydrolase (NH) of Leishmania donovani (NH36) and its epitopes in human visceral leishmaniasis. 2014
Antigenicity of F1, F2, F3 and NH36 in exposed individuals to L infantum. in Madrid (Spain). 2014
Cross-protective effect of vaccination with the recombinant chimera containing the N- and C- domains of Nucleoside hydrolase from Leishmania (L.) donovani terminals on prophylaxis of murine cutaneous leishmaniasis by Leishmania (L.) amazonensis. 2014
Quality of type 1 immune response induced by Leishmania (L.) donovani nucleoside hydrolase (NH36) peptides in peripheral blood mononuclear cells obtained from cutaneous leishmaniasis patients 2014
. Immucillins are potente compounds that impair Leishmania infantum and Leishmania amazonensis multiplication in vitro. 2014
Human influenza viruses inactivated by hydrostatic pressure: investigating a candidate for a universal vaccine 2014
A recombinant chimera containing the C- and N-terminal moieties of the Nucleoside hydrolase (NH36) of Leishmania (L.) donovani prophylaxis of mice against Leishmania (L.) infantum infection. 2014
Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+-epitopes of Leishmania donovani Nucleoside Hydrolase terminal. 2013
Vaccination with Nucleoside Hydrolase (NH36) of L. (L.) donovani or its C-terminal portion (F3) in formulation with saponin prevent the defective migration of dendritic cells in murine experimental visceral leishmaniasis. 2013
Vaccination with nucleoside Hydrolase (NH36) of L.(L.) donovani or its C-terminal portion (F3) in formulation with saponin prevent the defective migration of dendritic cells in murine experimental visceral leishmaniasis 2013
Immunization with the C-Terminal Domain Peptides of Leishmania (L.) donovani Nucleoside Hydrolase (NH36) aiming the identification of main epitopes 2012
Immunotherapy against Leishmania (L.) amazonensis infection with Nucleoside Hidrolase (NH36) peptides of Leishmania (L.) amazonensis 2012
Immunotherapy against Visceral Leishmaniasis with Nucleoside Hidrolase peptides of Leishmania (L.) donovani 2012
Cloning of the C-terminal domain peptides of Leishmania donovani nucleoside hydrolase (NH¨36) aiming the identification of antibody epitopes. 2011
Increase of the adjuvant capability of Chiococca alba saponin by the increase of one sugar residue in the C-28 triterpene attached sugar chain. Effect on protection against visceral leishmaniasis. 2011
Immunotherapy with the Leishmune's nucleoside hydrolase DNA vaccine reduces infection and increases survival in a canine 2011
Mice vaccination with H3N8 inactivated by high hydrostatic pressure protect against experimental avian flu. 2011
Partial contribution of the B2 receptor of the kinin inflamation pathway in protection against murine visceral leishmaniasis by the C-terminal domain of Nucleoside hydrolase vaccine. 2011
Vaccination with the Leishmune®´s Nucleoside Hydrolase Maps the C-Terminal Domain as the Target of the Protective Immune Response 2010
Comparison the Prophylactic Potential of the Nucleoside Hydrolase Genetic Vaccine on Visceral Leishmaniasis Administered in Mice through the Intramuscular or the Intranasal Route 2010
Comparison of Adjuvant Potential of a QS21-Containing Saponin and the CA3 and CA4 Saponins from Chiococca alba (L.) Hitch in Murine Vaccination against Visceral Leishmaniasis with the FML Antigen 2010
Inactivation by Hydrostatic Pressure Preserves the Hemagglutinin and Neuraminidase Activities of the Avian Influenza Virus H3N8 2010
VACCINATION WITH THE LEISHMUNE®´S NUCLEOSIDE HYDROLASE MAPS THE C-TERMINAL DOMAIN AS THE TARGET OF THE PROTECTIVE IMMUNE RESPONSE 2010
COMPARISON THE PROPHYLACTIC POTENTIAL OF THE NUCLEOSIDE HYDROLASE GENETIC VACCINE ON VISCERAL LEISHMANIASIS ADMINISTERED IN MICE THROUGH THE INTRAMUSCULAR OR THE INTRANASAL ROUTE 2010
Identification of the Leishmania donovani Nucleoside Hydrolase (NH36)-Peptide Sequences Containing Epitopes Involved in Protective Immune Response against Murine Visceral Leishmaniasis 2009
Development of a Second-Generation Vaccine against Dengue 2009
Cloning of the Nucleoside hydrolase of Leishmania donovani aiming the development of a synthetic vaccine against visceral leishmaniasis. 2008
Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis (CVL) 2008
Identification of potential MHC class I and II epitopes and cloning of the Nucleoside hydrolase of Leishmania donovani aiming the development of a synthetic vaccine against visceral leishmaniasis. 2007
Cross-protective efficacy of the prophylactic VR1012-NH36 Leishmania donovani-DNA vaccine against cutaneous murine leishmaniasis by Leishmania amazonensis 2007
Kinins generated upon vaccination with the QS21 saponin-containing Leishmune® vaccine are partially responsible for induction of protective immunity against visceral leishmaniasis 2007
Structure-function studies of the novel CP05 saponin of Calliandra pulcherrima Benth adjuvant: asseeement of monoterpene, glycidic fractions and triterpene in adjuvant function 2006
Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine agianst visceral leishmaniasis. 2006
Assentement of the monoterpene, glycidic and triterpene-moieties contribuition of the adjuvant function of the CP05-saponin of Calliandra pulcherrima Benth. 2006
The FML-vaccine Leishmune R against canine visceral leishmaniasis: a transmission blocking vaccine 2006
Comparative Adjuvant potential of the QS21 and CP05 purified saponins in the FML vaccine against murine visceral leishmaniasis 2005
Publicações:
Minha Rede: